I was going through older annual reports and thought of collating some of my notes here:
Annual Report 2010:
Turning science into caring, We advance leading edge science and technologies that hold the potential for significant improvement to health and practical health care.
Our mission in India: To be an admired organization and a leader in our core therapy areas by shaping the continuum of care be amongst the 3 fastest growing companies through 2015
Prominent brands: Brufen, Cremaffin and Digene are some of the heritage brands which have become household names in India. Epilex, Ganaton, Prothiaden, Sevorane, Survanta, Thyronorm and Zolfresh are among the other prominent market leading brands
Annual Report 2011:
Abbott, a global broad-based healthcare giant, enjoys a diversified presence in the discovery, development, manufacturing and marketing of innovative pharmaceutical, diagnostic, nutritional and hospital products.
We achieved a major milestone of merging two sterling companies, Abbott India Limited and Solvay Pharma India Limited, into one cohesive and integrated business. Thyronorm: Now No. 1 in Thyroid therapy area. Amongst Top 50 brands
of IPM. Heptral: One of the best product launches amongst MNCs in 2011 and
the best ever launch for Abbott India. Cremaffin: Crossed the milestone of Rs 100 Crores. The Company significantly outperformed the market, and its nearest rivals, in the core therapy areas in which it operates. As per IMS MAT Dec 2011, the market in which the Company participates grew by 16% versus the Company’s growth at 25%.
Annual Report 2012:
Headquartered in Mumbai, Abbott India Limited, a publicly listed company and a
subsidiary of Abbott Laboratories, enjoys strong brand equity in multiple therapeutic
categories such as Women’s Health, Gastroenterology, Neurology, Thyroid, Diabetes
& Urology, Pain Management, Vitamins, Anti-Infectives & other therapy areas. Abbott India is one of India’s fastest growing pharmaceutical companies. Abbott India’s success is driven by a combination of a highly competent and motivated commercial team, R&D backed products, aided by strong alliances and partnerships with our suppliers and vendors. Abbott India employs over 2,600 people and reaches customers through a network of 35 distribution points, catering to over 4,500 stockists and 150,000 retail outlets.
Digene continues to be # 1 prescribed Antacid with over 5.5 million prescriptions annually. Approximately 29,000 doctors prescribe Digene every month.
I am happy to report that your Company had another record year in 2012. Sales increased by 11.6% and Profit After Tax by 20.2% over prior year. This is a significant achievement considering the slower growth in the Indian Pharmaceutical Market at 11.1% vs.14.9% in the previous year.
We are currently in the process of completely overhauling our new product launch processes to double the number of new launches per year. These are being developed with a view to be early to launch new products and increase the success of new launches.
Annual Report 2013-14:
As you may be aware, implementation of the Drugs Prices Control Order (DPCO) 2013 had a significant impact on some of our major brands like Thyronorm, Obimet, Epilex. These brands faced new price limits which have directly impacted our profitability.
To cater to diverse and different health needs, we have a comprehensive range of products developed with leading scientific research and innovation that includes all stages of life and encapsulates most therapeutic areas.
As a connecting-link with patients, it is the doctors who are our key customers. We support them with research data and scientific information with cutting edge insights. These enable them to provide their patients more effective and useful health solutions.
In the Indian Pharmaceutical business which is dominated by a sea of generic formulations and me-too products, strong brands are equated with trust, faith and consistency. Our broad stable of more than 50 brands ensure strong relationships not only with doctors and healthcare professionals but also with patients and their care givers.
Annual Report 2015:
Our success, in large measure, has resulted from our focus and effective implementation of a three-pronged strategy - innovation in brand building; strong talent acquisition and people development; and flawless execution. Consumer Care division is a new focus area for the Company. Thyronorm, the market leader with 52.6% market share, continued its strong growth, growing at 41.2%* during the year This division grew by 19.4%*
during the year. Digene, the flagship brand of the division, was repositioned during the year as a more consumer focused brand.
Annual Report 2016:
Our solutions—across the spectrum of care and for all stages of life—help people live their best lives through better health.
At Abbott India, we always believe in outdoing ourselves. We grew our
Sales by 15.3% and Profit After Tax by 13.4%. Our PEOPLE give us the ability to execute our strategies. Our high-science PRODUCTS help generations of Indians lead better, healthier lives. Together, these deliver a PERFORMANCE that outpaces the market, our goals and your expectations.
Our strong portfolio of over 110 brands continues
to lead the Indian Pharmaceutical Market (IPM).
This year, 6 of our brands* were featured among the top 100 brands in the IPM, while 6 brands individually crossed Sales of Rs. 100 Crores.
We are not only attracting talent from the pharma sector but have a healthy mix of differentiated non-pharma talent from leading companies and top universities across the world to enable cross-pollination of ideas from across industries and sectors.
Annual Report 2017
At Abbott India, the key trigger to our business performance is that we offer quality, affordable medicines. We have an endless drive to bring meaningful innovation - in both the medicines and the services that go along with them - to help people live healthier fuller lives. We give people a reason to choose our medicines and this model has led to consistent and exceptional growth.
Annual Report 2018
We continued to take on the mantle of launching market shaping initiatives in collaboration with cross-industry players and technology partners, even when we encountered challenging circumstances on a few fronts.
We are here to help people lead fuller, healthier lives. And in this mission, it is imperative for us to gain patient insights. We also leverage technology to connect and engage with various stakeholders. Notable initiatives include Thyroweight, the country’s largest Thyroid Awareness program.
As we set our eye on the future, rapid inroads into sub-therapies, accelerated new product launches, innovative marketing and deployment of digital tools, steady deepening of relationships with the doctor, pharmacist, patient trio, continued strengthening and expansion of our brand portfolio, and the collective living of a shared vision by an over 3,300 strong employee pool, will continue to be the central levers of our growth momentum. Gutfit: A comprehensive program was
created, which enrolled high-risk patients and provided them with virtual counseling, wearable devices for tracking health metrics and customised diet plans.
Annual Report 2019
This is a landmark year. On August 22, 2019, your Company completes 75 years of its remarkable existence. On behalf of the entire Board, I would like to express my sincere gratitude to all of you – our dear shareholders, employees and business partners, for your constant support through the decades and for being part of our path-breaking journey. Your trust has been inspirational and instrumental in shaping our success over all these years. The future holds enormous promise.
We want to make room for “now” and “next” therapies, thereby addressing today’s demands while moving towards tomorrow’s challenges. We aim to accelerate our established brands through technical innovations that will add breadth and depth to our reach and scope as we serve patients, doctors, pharmacists and caregivers. We know that digital platforms will achieve maximum impact and dispersal in a market like India.
18 Likes